Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (145)	3/29/2000 10:16:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

latest wording, from 10-K..... The Company retained ownership of all its other assets, including its core yeast technology for developing drug discovery assays, its collection of over 25,000 proprietary yeast strains, human and mammalian cell lines, and genetic engineering tools, its joint ownership of the human orphan G Protein-coupled receptors identified pursuant to its collaboration with Genomic Therapeutics Corporation, its proprietary software, its genomics databases related to G Protein-coupled receptors, all assays and technologies reverting to it from its collaboration with Bristol-Myers Squibb Company, a 30% equity position in Axiom Biotechnologies Inc., the Company's cash and cash equivalents, and the approximately $19.1 million being held in escrow pending appeal of the verdict in favor of SIBIA.